The SMYD2, SET, and MYND domain-containing protein 2, a lysine methyltransferase, is aberrantly dysregulated in different cancer types, inducing several mitogenic signaling pathways by methylating lysine moieties, activating multiple oncogenic and effector proteins [7,8]. The gene discussed is SMYD2; the disease is cancer.